Aspira Women's Health Inc. business relationships
Companies named in Aspira Women's Health Inc.’s 10-K filed 2026-04-01, and public companies whose annual reports name Aspira Women's Health Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.4 / 10
- AI naming
- 72 / 100 Top 1% in its category
- Agent readiness
- 5 / 100
- AI adoption
- 10 / 100
Named in Aspira Women's Health Inc.’s annual report 6
“License Agreement between Aspira Women's Health Inc. and Dana-Farber Cancer Institute, Inc. effective March 20, 2023” SEC filing
“Our principal supplier for the component reagents is Roche Diagnostics Corporation.” SEC filing
“The purpose of the 2025 amendment was to add OvaWatch to the U.S testing services for Quest Diagnostics customers and to extend the term of the agreement from December 31, 2023 to December 31, 2025.” SEC filing
“| | ● | | expectations regarding continuing future services provided by Quest Diagnostics Incorporated; |” SEC filing
“The Company also engages in channel distribution partnerships by which OvaSuite is distributed via laboratory partners such as BioReference Health, LLC. and ARUP.” SEC filing
“| | ● | | expectations regarding continuing future services provided by BioReference Health, LLC; |” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.